Substituted anilines as CCR(4) antagonists
US11142521B2 · kind B2 · utility
3Cited by
4References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 2019 |
| Grant date | Oct 12, 2021 |
| Priority date | — |
| Expiry date | Jul 30, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.